Bimekizumab
drugOn this page
Also known as Bimekizumab-bkzxBimzelxUCB-4940Ucb4940
Summary
Bimekizumab (CHEMBL4297700) is an approved antibody (ATC L04AC21); indicated across 7 conditions including psoriasis and immune system disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Antibody
- ATC class: L04AC21
- Indications: 7 conditions
- Clinical trials: 52
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297700 |
| Name | Bimekizumab |
| Type | Antibody |
| Max phase | 4 |
| ATC | L04AC21 |
Also known as: Bimekizumab, Bimekizumab-bkzx, Bimzelx, UCB-4940, Ucb4940, UCB4940, BIMEKIZUMAB
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
7 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| psoriasis | 4 | MONDO:0005083 | EFO:0000676 |
| immune system disorder | 4 | MONDO:0005046 | EFO:0000540 |
| parapsoriasis | 4 | MONDO:0006592 | EFO:1000747 |
| psoriatic arthritis | 3 | MONDO:0011849 | EFO:0003778 |
| ankylosing spondylitis | 3 | MONDO:0005306 | EFO:0003898 |
| hidradenitis suppurativa | 3 | MONDO:0006559 | EFO:1000710 |
| rheumatoid arthritis | 2 | MONDO:0008383 | EFO:0000685 |
Clinical trials
Total trials: 52.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 24 |
| PHASE2 | 14 |
| PHASE1 | 8 |
| PHASE4 | 5 |
| Not specified | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT07352566 | PHASE4 | NOT_YET_RECRUITING | Utilization of a Microdevice for Psoriasis and Atopic Dermatitis |
| NCT07497620 | PHASE4 | NOT_YET_RECRUITING | Bimzelx (Bimekizumab) For The Treatment Of Adult Onset PRP |
| NCT04340076 | PHASE4 | COMPLETED | Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis |
| NCT05499416 | PHASE4 | WITHDRAWN | Effect of Bimekizumab in Patients With Psoriasis Vulgaris and Active Psoriatic Arthritis |
| NCT06336343 | PHASE4 | COMPLETED | Bimekizumab in Plaque Psoriasis |
| NCT04009499 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Assess the Long-term Safety, Tolerability, and Efficacy of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis |
| NCT04436640 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Subjects With Active Axial Spondyloarthritis Including Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis |
| NCT04901195 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa |
| NCT06425549 | PHASE3 | RECRUITING | A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab in Children and Adolescents From 6 Years to Less Than 18 Years of Age With Moderate to Severe Plaque Psoriasis |
| NCT06506916 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis |
| NCT06624228 | PHASE3 | ACTIVE_NOT_RECRUITING | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Study Participants With Active Psoriatic Arthritis |
| NCT06668181 | PHASE3 | RECRUITING | An Open-label Study to Evaluate the Pharmacokinetics and Safety of Bimekizumab in Pediatric Study Participants With Active Juvenile Idiopathic Arthritis Subtypes Enthesitis-related Arthritis (Including Juvenile-onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis |
| NCT06921850 | PHASE3 | RECRUITING | A Study to Assess the Pharmacokinetics and Safety of Bimekizumab in Children and Adolescents With Moderate to Severe Hidradenitis Suppurativa |
| NCT07219420 | PHASE3 | RECRUITING | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis |
| NCT03370133 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis |
| NCT03410992 | PHASE3 | COMPLETED | A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis |
| NCT03412747 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis |
| NCT03536884 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis |
| NCT03598790 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis |
| NCT03766685 | PHASE3 | COMPLETED | A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO) |
| NCT03895203 | PHASE3 | COMPLETED | A Study to Test the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis |
| NCT03896581 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Bimekizumab in the Treatment of Subjects With Active Psoriatic Arthritis |
| NCT03928704 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Nonradiographic Axial Spondyloarthritis |
| NCT03928743 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Subjects With Active Ankylosing Spondylitis |
| NCT04109976 | PHASE3 | COMPLETED | A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Active Psoriatic Arthritis |
| NCT04242446 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa |
| NCT04242498 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa |
| NCT05020249 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Adult Korean Study Participants With Moderate to Severe Plaque Psoriasis |
| NCT06011733 | PHASE3 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Bimekizumab in Chinese Adult Study Participants With Moderate to Severe Plaque Psoriasis |
| NCT06742333 | PHASE2 | RECRUITING | Early Intervention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflammation? |
| NCT07138898 | PHASE2 | NOT_YET_RECRUITING | Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty |
| NCT02430909 | PHASE2 | COMPLETED | Multiple Dose Study of UCB4940 as add-on to Certolizumab Pegol in Subjects With Rheumatoid Arthritis |
| NCT02905006 | PHASE2 | COMPLETED | Study to Evaluate Safety and Efficacy of Different Doses of Bimekizumab in Patients With Chronic Plaque Psoriasis |
| NCT02963506 | PHASE2 | COMPLETED | A Study to Evaluate the Efficacy and Safety of Different Doses of Bimekizumab in Subjects With Active Ankylosing Spondylitis |
| NCT02969525 | PHASE2 | COMPLETED | A Study to Evaluate the Dose Response Based on the Efficacy, Safety and Tolerability of Bimekizumab in Subjects With Active Psoriatic Arthritis Which is a Type of Inflammatory Arthritis |
| NCT03010527 | PHASE2 | COMPLETED | A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis |
| NCT03025542 | PHASE2 | COMPLETED | A Study to Evaluate the Pharmacokinetics (PK), Pharmacodynamics (PD), and Safety of Bimekizumab in Patients With Chronic Plaque Psoriasis |
| NCT03215277 | PHASE2 | COMPLETED | A Study to Test the Efficacy and Safety of Bimekizumab and Certolizumab Pegol in Patients With Active Ankylosing Spondylitis |
| NCT03230292 | PHASE2 | COMPLETED | A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Adult Patients With Chronic Plaque Psoriasis |
| NCT03248531 | PHASE2 | COMPLETED | A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa. |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).